Total liabilities and shareholders' equity Total Biogen Idec Inc. shareholders' equity Accumulated other comprehensive income Retained earnings Treasury stock, at cost Additional paid-in capital Preferred stock, par value $0.001 per share Common stock, par value $0.0005 per share Other long-term liabilities Total liabilities Notes payable and line of credit Long-term deferred tax liability Current liabilities: Total current liabilities Current portion of notes payable and line of credit Accrued expenses and other Total assets Marketable securities Property, plant and equipment, net Intangible assets, net Goodwill Investments and other assets Total current assets Inventory Other current assets We loan certain securities from our portfolio to other institutions. Such securities are classified as loaned securities on the accompanying consolidated balance sheet. Collateral for the loaned securities, consisting of cash or other securities is maintained at a rate of approximately 102% of the market value of each loaned security. The cash collateral is recorded as collateral received for loaned securities on the consolidated balance sheet. We have a current obligation to return the collateral which is reflected as collateral received on loaned securities on the accompanying consolidated balance sheet. Income received from lending securities is recorded in other income (expense), net. Loaned securities Accounts receivable, net Marketable securities Cash and cash equivalents, beginning of the period Preferred stock, par value Common stock, par value ASSETS Current assets: LIABILITIES AND SHAREHOLDERS' EQUITY Collaborations [Abstract] Collaborations [Abstract] Collaborations. Litigation [Abstract] Litigation [Abstract] Litigation. Segment Information [Abstract] Segment Information [Abstract] Segment Information. New Accounting Pronouncements Inventory Intangible Assets and Goodwill Fair Value Measurements Income Taxes Segment Information Collateral received for loaned securities Collateral received for loaned securities We loan certain securities from our portfolio to other institutions. Such securities are classified as loaned securities on the accompanying consolidated balance sheet. Collateral for the loaned securities, consisting of cash or other securities is maintained at a rate of approximately 102% of the market value of each loaned security. The cash collateral is recorded as collateral received for loaned securities on the consolidated balance sheet. We have a current obligation to return the collateral which is reflected as collateral received on loaned securities on the accompanying consolidated balance sheet. Income received from lending securities is recorded in other income (expense), net. Collateral payable on loaned securities Collateral payable on loaned securities We loan certain securities from our portfolio to other institutions. Such securities are classified as loaned securities on the accompanying consolidated balance sheet. Collateral for the loaned securities, consisting of cash or other securities is maintained at a rate of approximately 102% of the market value of each loaned security. The cash collateral is recorded as collateral received for loaned securities on the consolidated balance sheet. We have a current obligation to return the collateral which is reflected as collateral received on loaned securities on the accompanying consolidated balance sheet. Income received from lending securities is recorded in other income (expense), net. Weighted-average shares used in calculating: Basic earnings per share attributable to Biogen Idec Inc. Diluted earnings per share attributable to Biogen Idec Inc. Diluted earnings per share attributable to Biogen Idec Inc. Basic earnings per share attributable to Biogen Idec Inc. Net income attributable to Biogen Idec Inc. Income tax expense Income before income tax expense Other income (expense), net Income from operations Costs and expenses: Total costs and expenses Research And Development In Process Amortization of acquired intangible assets Collaboration profit sharing Collaboration profit sharing Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of Tysabri outside the U.S. increase, our collaboration profit sharing expense will increase. Selling, general and administrative Research and development Cost of sales, excluding amortization of acquired intangible assets Revenues: Total revenues Other revenues Product Cash and cash equivalents, end of the year Cash and cash equivalents, beginning of the year Effect of exchange rate changes on cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash flows from financing activities: Net cash flows used in financing activities Obligation under securities lending Obligation under securities lending This is the liability that is maintain on the Company ledger to offset the fact we loan certain securities from our portfolio to other institutions. As such securities transaction are classified as loaned securities on the accompanying consolidated cash flow. Collateral for the loaned securities, consisting of cash or other securities is maintained at a rate of approximately 102% of the market value of each loaned security. We have a current obligation to return the collateral which is reflected as collateral received on loaned securities on the accompanying consolidated cash (out) flow. Repayment of borrowings Proceeds from borrowings Change in cash overdraft Proceeds from issuance of stock for share-based compensation arrangements Purchase of treasury stock Cash flows from investing activities: Net cash flows used in investing activities Collateral received under securities lending We loan certain securities from our portfolio to other institutions. As such securities transactions are classified as loaned securities on the accompanying consolidated cash flow. Collateral for the loaned securities, consisting of cash or other securities is maintained at a rate of approximately 102% of the market value of each loaned security. The cash collateral is recorded as collateral received for loaned securities as cash (in) flows. Purchases of other investments Acquisitions, net of cash acquired Purchases of property, plant and equipment Proceeds from sales and maturities of marketable securities Purchases of marketable securities Other liabilities and taxes payable Accrued expenses and other current liabilities Other assets Inventory Accounts receivable Realized loss (gain) on sale of marketable securities and strategic investments Deferred income taxes Non-cash interest (income) expense and foreign exchange remeasurement loss (gain), net Share-based compensation Depreciation and amortization of fixed and intangible assets Cash flows from operating activities: Ending Balance Beginning Balance Collateral received under securities lending Collaborations Litigation Litigation Text Block Litigation. Net cash flows provided by operating activities Net income attributable to Biogen Idec Inc. Marketable securities Marketable Securities, Noncurrent Collaboration profit sharing Collateral received for loaned securities Loaned securities Collateral payable on loaned securities Collateral received under securities leading Obligation under securities lending Collaborations [Abstract] Litigation [Abstract] Segment Information [Abstract] Unconsolidated joint business Unconsolidated joint business Revenues from unconsolidated joint business consists of our share of pretax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pretax co-promotion profits in Canada. Due from unconsolidated joint business Due from unconsolidated joint business Receivable from unconsolidated joint business for our share of the pretax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN. Impairment of marketable securities, investments and other assets Impairment of investments and other assets Treasury stock, at cost; 0 and 9,207 shares at December 31, 2009 and 2008, respectively Realized (gain) loss on sale of marketable securities and strategic investments Gain (Loss) on Investments Purchases of marketable securities Acquisitions, net of cash acquired Purchases of property, plant and equipment Purchase of other investments Proceeds from sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Non-cash interest (income) expense and foreign exchange remeasurement loss (gain), net Product Sales Revenue, Goods, Net Cost of sales, excluding amortization of acquired intangible assets Cost of Revenue Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Other income (expense), net Other Nonoperating Income (Expense) Income tax expense Income Tax Expense (Benefit) Cash and cash equivalents Cash and Cash Equivalents, at Carrying Valu Marketable securities Marketable Securities, Current Accounts receivable, net of allowances of $43,818 and $32,047 at December 31, 2009 and 2008, respectively Accounts Receivable, Net, Current Inventory Inventory, Net Property, plant and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Current portion of notes payable and line of credit Notes Payable, Current Notes payable and line of credit Long-term Notes Payable Additional paid-in capital Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Ending Balance Additional Paid in Capital Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance Accumulated Other Comprehensive Income (Loss), Net of Tax Retained earnings Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit) Net income Depreciation and amortization of property, plant and equipment and intangible assets Depreciation and Amortization Share-based compensation Share-based Compensation Inventory Increase (Decrease) in Inventories Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Proceeds from borrowings Proceeds from Short-term Debt Repayments of borrowings Repayments of Short-term Debt Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Revenues: Other revenues Costs and expenses: Amortization of acquired intangible assets Amortization of Intangible Assets, Total Acquired in process research and development and license Basic earnings per share attributable to Biogen Idec Inc. Diluted earnings per share attributable to Biogen Idec Inc. Basic earnings per share attributable to Biogen Idec Inc. Earnings Per Share, Basic Diluted earnings per share attributable to Biogen Idec Inc. Earnings Per Share, Diluted ASSETS Current assets: Other current assets Goodwill Goodwill, Beginning Balance Goodwill, Ending Balance Investments and other assets Investments and other assets Accrued expenses and other Other Liabilities, Current, Total Long-term deferred tax liability Other long-term liabilities Other long-term liabilities Preferred stock, par value $0.001 per share (8,000 shares authorized, of which 1,750 are designated Series A and 1,000 are designated Series X Junior Participating; 8 shares of Series A issued and outstanding with a $551 liquidation value at December 31, 2009 and 2008) Preferred Stock, Value, Total Preferred Stock, Value, Beginning Balance Preferred Stock, Value, Ending Balance Common stock, par value $0.0005 per share (1,000,000 shares authorized; 288,494 shares issued and 274,855 shares outstanding at December 31, 2009; 297,253 shares issued and 288,046 shares outstanding at December 31, 2008) Common Stock, Value, Total Common Stock, Value, Beginning Balance Common Stock, Value, Ending Balance Current liabilities: LIABILITIES AND SHAREHOLDERS' EQUITY Preferred stock, par value Common stock, par value Cash flows from operating activities: Non-cash interest (income) expense and foreign exchange remeasurement, net Deferred income taxes Deferred Income Tax Expense (Benefit), Total Accounts receivable Other assets Other liabilities and taxes payable Cash flows from investing activities: Purchases of marketable securities Payments to Acquire Marketable Securities Acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Purchase of other investments Cash flows from financing activities: Purchase of treasury stock Proceeds from issuance of stock for share-based compensation arrangements Change in cash overdraft Proceeds from the sale of strategic investments Proceeds From The Sale Of A Strategic Equity Investment Proceeds from the sale of a strategic equity investment. Inventory Intangible Assets and Goodwill Fair Value Measurements Income Taxes New Accounting Pronouncements Segment Information Collaborations Other Acquired in-process research and development Income from operations Operating Income (Loss) Income before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Minority Interest, and Income (Loss) from Equity Method Investments Basic earnings per share attributable to Biogen Idec Inc. Diluted earnings per share attributable to Biogen Idec Inc. Other current assets Other liabilities and taxes payable Proceeds from the sale of a strategic equity investment Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Treasury Stock, Value, Beginning Balance Treasury Stock, Value, Ending Balance Treasury stock, at cost Stockholders' Equity Treasury stock, at cost Liabilities and Stockholders' Equity Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Excess tax benefit from stock options Excess Tax Benefit from Share-based Compensation, Operating Activities Excess tax benefit from stock options Excess Tax Benefit from Share-based Compensation, Financing Activities Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Statement [Table] Statement [Line Items] Revenues Costs and Expenses Assets, Current Assets Liabilities, Current Liabilities Accounts payable Accounts Payable, Current, Total Accounts Payable, Current Commitments and contingencies (Notes 16, 17, 18 and 19) Commitments and Contingencies Taxes payable Taxes payable Taxes Payable, Current Write-down of inventory to net realizable value Inventory Write-down Adjustments to reconcile net income to net cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Total shareholders' equity Beginning Balance Ending Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance Stockholders' Equity Attributable to Noncontrolling Interest Total Biogen Idec Inc. shareholders' equity Net income (loss) attributable to noncontrolling interest, net of tax Net Income (Loss) Attributable to Noncontrolling Interest Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment, Total Proceeds from Sale of Property, Plant, and Equipment Due from unconsolidated joint business Increase Decrease In Due From Unconsolidated Joint Business Increase Decrease In Due From Unconsolidated Joint Business. Net Cash Provided by (Used in) Investing Activities Earnings per Share Earnings Per Share [Text Block] Treasury stock, at cost; 13,639 and 9,207 shares at December 31, 2009 and 2008, respectively Shareholders' Equity: Share-based Payments Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Purchases of marketable securities Acquisitions, net of cash acquired Purchases of property, plant and equipment Purchase of treasury stock Repayments of borrowings Obligation under securities lending Document and Company Information [Abstract] Document And Company Information [Abstract] Document and Company Information. Statements of Income [Abstract] Balance Sheets [Abstract] Statements of Cash Flows [Abstract] Inventory [Abstract] Inventory [Abstract] Net income per share: Earnings per Share [Abstract] New Accounting Pronouncements [Abstract] New Accounting Pronouncements [Abstract] Income Taxes [Abstract] Share-based Payments [Abstract] Derivative Instruments [Abstract] Derivative Instruments [Abstract] Equity [Abstract] Sahreholders' Equity [Abstract] Income Taxes [Abstract] Balance Sheets [Abstract] Statements of Cash Flows [Abstract] Share-Based Payments [Abstract] Repayments of Long-term Debt, Total Repayments of long-term debt Repayments of Long-term Debt Treasury stock reclassification Treasury Stock Reclassification In the year ended December 31, 2007 we reclassified amounts within the statements of stockholders equity, resulting in correction in the treasury stock and common stock balances. Issuance of treasury stock under stock award plans, shares Issuance Of Treasury Stock Under Stock Award Plans Issuance of treasury stock under stock award plans. Issuance of treasury stock under stock award plans Issuance Of Treasury Stock Under Stock Award Plan Issuance of treasury stock under stock award plans. Issuance of treasury stock under stock option and stock purchase plans, shares Issuance Of Treasury Stock Under Stock Option And Stock Purchase Plans Issuance of treasury stock under stock option and stock purchase plans. Issuance of treasury stock under stock option and stock purchase plans Issuance of treasury stock under stock option and stock purchase plan Issuance of treasury stock under stock option and stock purchase plans. Issuance of treasury stock from conversion of subordinated notes payable, shares Issuance Of Treasury Stock From Conversion Of Subordinated Notes Payable Issuance of treasury stock from conversion of subordinated notes payable. Issuance of treasury stock from conversion of subordinated notes payable Issuance of treasury stock from conversion of subordinated notes payable value Issuance of treasury stock from conversion of subordinated notes payable. Fair value of assets and liabilities acquired and assigned to noncontrolling interest due to the adoption of a new accounting standard for the consolidation of variable interests Fair Value Of Assets And Liabilities Acquired And Assigned To Noncontrolling Interest Through Initial Consolidation Fair value of assets and liabilities acquired and assigned to noncontrolling interest due to the adoption of a new accounting standard for the consolidation of variable interests. Treasury stock reclassifications, shares Treasury stock reclassification, shares In the year ended December 31, 2007 we reclassified amounts within the statements of stockholders equity, resulting in correction in the treasury stock and common stock balances. Treasury stock reclassifications Comprehensive income: Comprehensive Income, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Tax benefit from share-based payments Adjustments to Additional Paid in Capital, Tax Effect from Share-based Compensation Compensation expense related to share-based payments Allocated Share-based Compensation Expense Compensation expense related to share-based payments Adjustment for adoption for accounting of uncertain tax positions Cumulative Effect of Initial Adoption of FIN 48 Forfeiture of common stock under restricted stock plan, shares Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Forfeiture of common stock under restricted stock plan Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Issuance of common stock under stock award plans, shares Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of common stock under stock award plans Stock Issued During Period, Value, Restricted Stock Award, Gross Repurchase and retirement of common stock pursuant to tender offer, shares Stock Repurchased and Retired During Period, Shares Repurchase and retirement of common stock pursuant to tender offer Stock Repurchased and Retired During Period, Value Capital contribution from noncontrolling interest Noncontrolling Interest, Increase from Stock Issuance or Sale of Parent Equity Interest Distribution to noncontrolling interest Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Total comprehensive income Total comprehensive income Comprehensive Income, Net of Tax, Including Portion Attributable to Noncontrolling Interest Translation adjustment Translation adjustment Other Comprehensive Income, Foreign Currency Transaction and Translation Adjustment, Net of Tax Unrealized loss on pension benefit obligation, net of tax of ($67), $0 and ($370) for year 2009, 2008 and 2007, respectively Other Comprehensive Income, Defined Benefit Plan's Net Unamortized (Gain) Loss Arising During Period, Net of Tax Tax effect on unrealized gains on pension benefit obligation Other Comprehensive Income, Defined Benefit Plan's Net Unamortized Gain (Loss) Arising During Period, Tax Tax effect on unrealized gains on securities available for sale Other Comprehensive Income, Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax Interest Interest Paid, Net, Total Interest Paid, Net Income taxes Income Taxes Paid, Net, Total Income Taxes Paid, Net Non cash financing activity [Abstract] Non-cash financing activity Non-cash financing activity: Supplemental cash flow disclosures: Supplemental Cash Flow Information [Abstract] Issuance of common stock under stock option and stock purchase plans, shares Issuance of common stock under stock option and stock purchase plans Shares Issuance of common stock under stock option and stock purchase plans. Issuance of common stock under stock option and stock purchase plans Issuance of common stock under stock option and stock purchase plan Issuance of common stock under stock option and stock purchase plans. Issuance of common stock from conversion of subordinated notes payable, shares Stock Issued During Period, Shares, Conversion of Convertible Securities Issuance of common stock from conversion of subordinated notes payable Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of subordinated notes to common and treasury stock Conversion of subordinated notes to common and treasury stock Conversion of subordinated notes to common and treasury stock. Tax effect on unrealized loss on foreign currency forward contracts Other Comprehensive Income, Unrealized Gain (Loss) on Derivatives Arising During Period, Tax Commitments and Contingencies [Abstract] Commitments and Contingencies. Commitments And Contingencies Disclosure [TextBlock] Acquisitions and Dispositions [Abstract] Acquisitions and Dispositions. Acquisitions and Dispositions Acquisitions and Dispositions Text Block A textual description of the key elements that define a specific acquisition or disposal. Accumulated Other Comprehensive Income (Loss) Comprehensive Income Note [Text Block] Indebtedness Debt Disclosure [Text Block] Employee Benefit Plans Pension and Other Postretirement Benefits Disclosure [Text Block] Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] Quarterly Financial Data (Unaudited) [Abstract] Guarantees [Abstract] Guarantees. Schedule of Guarantor Obligations [Text Block] Guarantees Beginning Balance, shares Ending Balance, shares Shares, Issued Class of Stock [Axis] Class of Stock [Domain] Allowance for Doubtful Accounts Receivable, Current Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Preferred Stock, Liquidation Preference Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Statements of Equity [Abstract] Other Comprehensive Income, Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Other Comprehensive Income, Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Statement, Equity Components [Axis] Equity Component [Domain] Biogen Idec Inc. Shareholders Equity Common Stock Preferred Stock Additional Paid-in Capital Treasury Stock Retained Earnings/(accumulated deficit) Accumulated other comprehensive income Noncontrolling Interest Accumulated Other Comprehensive Income (Loss) [Abstract] Employee Benefit Plans [Abstract] Unrealized loss on securities available for sale, net of tax of ($379), ($1,123) and ($3,984) for year 2009, 2008 and 2007, respectively Unrealized gains on foreign currency forward contracts, net of tax of ($3,582), $1,522 and $2,263 for year 2009, 2008 and 2007, respectively Convertible Preferred Stock Common Stock Additional Paid-in Capital Accumulated other comprehensive income Retained Earnings/(accumulated deficit) Treasury Stock Biogen Idec Inc. Shareholders Equity Noncontrolling Interest Treasury stock, at cost Treasury Stock, Shares, Beginning Balance Treasury Stock, Shares, Ending Balance Treasury Stock, Shares Series X Junior Participating Preferred Stock Series X Junior Participating Preferred Stock Series X Preferred Stock Member. Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Common stock, shares issued Common Stock, Shares, Issued, Total Common stock, shares authorized Preferred stock, liquidation value per share of Series A Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred stock, shares authorized Allowance for doubtful accounts receivable, current Allowance for Doubtful Accounts Receivable, Current, Beginning Balance Allowance for Doubtful Accounts Receivable, Current, Ending Balance Series A Preferred Stock Series A Preferred Stock Commitments and Contingencies Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Other Consolidated Financial Statement Detail [Abstract] Other Consolidated Financial Statement Detail [Abstract] Other Consolidated Financial Statement Detail. Summary of Significant Accounting Policies [Abstract] Summary of Significant Accounting Policies [Abstract] Cash paid during the year for: Cash paid during the year for Abstract Cash paid during the year for: Acquired in-process research and development Acquired in-process research and development The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. Other Consolidated Financial Statement Detail Other Consolidated Financial Statement Detail Text Block Disclosure showing Gains on Dispositions, Other Income & Expenses, Property, Plant & Equipment, Other Current Assets, and Accrued Expenses & Other. Gain on disposition, net Gains (Losses) on Sales of Assets Gain on sale of property, plant and equipment, net Changes in operating assets and liabilities, net: Increase (Decrease) in Operating Capital [Abstract] Cash received upon termination of interest rate swap Cash received upon termination of interest swap Cash received upon the termination of interest rate swaps utilized to mange our exposures in interest rates. Interest rates are contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period. Gain on dispositions, net Gain on sale of property, plant and equipment, net Derivative Instruments Derivative Instruments Text Block This note represents our disclosures related to: our hedging activities and use of derivative instruments; which includes disclosure related to our use of forward currency contracts to mitigate the risk of change in exchange rates and our use of interest rates swaps to manage our exposure to changes in interest rates and each of their respective notational amounts. Disclosures may also include the effect, if any, on our consolidated financial position and results of operations related to derivatives designated as hedging instruments. Financial Instruments Financial Instruments Text Block This note represents our disclosures related to: (1) Marketable Securities, Non-Marketable Securities and Other Investments which may consist of all investments in certain debt and equity securities (and other assets); including: securities held-to-maturity, trading securities, securities available-for-sale, and non-marketable securities; and (2) any unrealized gains and losses recognized on our investments due to changes in fair value as well as amounts charged to income if a decline in fair value of our investments is deemed to be other than temporary. Fair Value Measurements [Abstract] Fair Value Measurements Abstract. Intangible Assets and Goodwill [Abstract] Intangible Assets And Goodwill Abstract. Repurchase of common stock for Treasury, at cost Treasury Stock, Value, Acquired, Cost Method Repurchase of common stock for Treasury, shares Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Financial Instruments [Abstract] Financial Instruments [Abstract] FinancialInstrumentsAbstract. Payments to Noncontrolling Interests Reserves [Abstract] Reserves Abstract. Reserves Reserves Text Block Represents disclosure of our revenue recognition policies and accounting for related reserves for discounts and allowances. This item also provides analyses of the amount of, and change in, total revenue reserves related to our product sales. Indebtedness [Abstract] Indebtedness Abstract. Net distribution from noncontrolling interest Net capital contribution from noncontrolling interest Realized (gain) loss on sale of marketable securities and strategic investments Total current liabilities Treasury stock reclassifications, shares Retirement of common stock pursuant to 2009 stock repurchase plan Retirement Of Common Stock Retirement Of Common Stock. Retirement of common stock pursuant to 2009 stock repurchase plan, shares Retirement Of Common Stock Shares Retirement Of Common Stock Shares. In the year ended December 31, 2008, we reclassified amounts within the statement of shareholder's equity, resulting in an correction in Additional Paid-in Capital and Retained Earnings (Accumulated Deficit) balances in connection with the re-issuance of treasury stock at a loss. Treasury Stock Reclassifications Treasury stock reclassifications Shareholders' Equity Shareholders Equity Text Block Information about Shareholders Equity including Preferred Stock, Stockholders right plans, Stock repurchase programs and reclassifications.